scPharmaceuticals (FRA:2SX) Debt-to-Asset : 0.49 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is scPharmaceuticals Debt-to-Asset?

scPharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.23 Mil. scPharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €50.09 Mil. scPharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was €102.68 Mil. scPharmaceuticals's debt to asset for the quarter that ended in Dec. 2024 was 0.49.

scPharmaceuticals Debt-to-Asset Historical Data

The historical data trend for scPharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

scPharmaceuticals Debt-to-Asset Chart

scPharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.19

0.22

0.30

0.43

0.49

scPharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.43	0.52	0.63	0.42	0.49

Competitive Comparison of scPharmaceuticals's Debt-to-Asset

For the Biotechnology subindustry, scPharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

scPharmaceuticals's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, scPharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where scPharmaceuticals's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

scPharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

scPharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.228	+	50.094)	/	102.681
	=	0.49

scPharmaceuticals's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.228	+	50.094)	/	102.681
	=	0.49

scPharmaceuticals (FRA:2SX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

scPharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of scPharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

scPharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » scPharmaceuticals Inc (FRA:2SX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

SCPH:USA 2SX:Germany

Address

25 Mall Road, Suite 203, Burlington, MA, USA, 01803

Website

https://www.scpharmaceuticals.com

scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.

scPharmaceuticals Headlines

No Headlines